Skip to content

HELIX DIAGNOSTICS

Comprehensive Pharmacogenomics (PGx) Panel

Panel Description

Many medications are impacted by specific variations in known genes. These genetic variations can contribute to medication efficacy and risk for side effects. Pharmacogenomic testing to guide prescribing, paired with clinical monitoring can impact outcomes for patients by reducing the time to therapeutic effect and reducing the risk of side effects.

This test evaluates a patient’s metabolizer status for 26 genes, which can aid in appropriate medication selection and dosing to reduce risk of side effects and treatment failure for cancer, cardiovascular disease, pain, mental health and other conditions.

Genes Tested (26)

Scroll down for more

ABCB1
ABCG2
ATIC
COMT
CYP2C cluster
CYP2C19
CYP2C9
CYP2D6
CYP3A4
CYP3A5
CYP4F2
DPYD
F2
F5
GRK4
HLA-B
IFNL3
IFNL4
MT-RNR1
MTHFR
NUDT15
OPRM1
SLC19A1
SLCO1B1
TPMT
VKORC1

Important Panel Information

Turnaround time: 7-10 days

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

Patients for whom medication from the following list are being considered, have been ineffective, or caused side effects: Abacavir, Allopurinol, Amikacin, Amitriptyline, Amphetamine, Aripiprazole, Atomoxetine, Atorvastatin, Azathioprine, Brexpiprazole, Brivaracetam, Capecitabine, Carbamazepine, Celecoxib, Citalopram, Clobazam, Clomipramine, Clopidogrel, Clozapine, Codeine, Desipramine, Deutetrabenazine, Dexlansoprazole, Doxepin, Escitalopram, Flecainide, Flibanserin, Fluorouracil, Flurbiprofen, Fluvastatin, Fluvoxamine, Gefitinib, Gentamicin, Haloperidol, Hydrocodone, Ibuprofen, Iloperidone, Imipramine, Kanamycin, Lamotrigine, Lansoprazole, Lofexidine, Lornoxicam, Lovastatin, Meloxicam, Mercaptopurine, Metoprolol, Nortriptyline, Oliceridine, Omeprazole, Ondansetron, Oxcarbazepine, Pantoprazole, Paroxetine, Peginterferon alfa-2a, Peginterferon alfa-2b, Pimozide, Piroxicam, Pitavastatin, Plazomicin, Pravastatin, Propafenone, Quetiapine, Risperidone, Rosuvastatin, Sertraline, Simvastatin, Streptomycin, Tacrolimus, Tamoxifen, Tegafur, Tenoxicam, Thioguanine, Thioridazine, Tobramycin, Tramadol, Trimipramine, Tropisetron, Valbenazine, Venlafaxine, Voriconazole, Vortioxetine, and Warfarin

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.

Other Tests to Consider

Pharmacogenomics (PGx) APOE Panel

Pharmacogenomics (PGx) Pain Panel

6 genes

Pharmacogenomics (PGx) Proton Pump Inhibitors CYP2C19 Panel

Pharmacogenomics (PGx) Tacrolimus CYP3A5 Test